Original Research Article

A prospective study of efficacy and safety of olopatadine versus azelastine in allergic conjunctivitis at a tertiary care hospital

Jayanthi C. R., Nanthini R.*, Vijalakshmi

ABSTRACT

Background: Allergic conjunctivitis, an ocular surface inflammatory disease with significant social and economic impact affects approximately 25% of the general population. H1 receptor blockers, mast cell stabilizers and drugs that block cytokine and prostaglandin formation form the treatment armamentarium. Olopatadine hydrochloride and Azelastine hydrochloride are dual-acting selective H1 receptor antagonist with mast-cell stabilizing property. This study was undertaken to assess the efficacy and safety of olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% in allergic conjunctivitis amongst Indians.

Methods: After obtaining Institutional Ethics Committee approval and written informed consent, 120 patients diagnosed with allergic conjunctivitis fulfilling the inclusion/exclusion criteria were enrolled in the study. Study was done from April 2014 to June 2015 at Minto eye hospital. Study subjects were treated with olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% eye drops BD for 15 days. Ocular symptoms, instead of and signs and adverse events, if any were recorded on the day 8 and day 15 follow up visits.

Results: At the end of the study period, the reduction in the ocular itching score from baseline was higher in the olopatadine group compared to the azelastine group (p<0.002). Similarly, the scores of ocular congestion (p<0.008), foreign body sensation (p<0.009), tearing (p<0.001), erythema (p<0.002) and chemosis (p<0.015) also showed larger reduction in the olopatadine treated patients. The common adverse events encountered in both the groups were stinging after instillation, burning, bitter taste and headache.

Conclusions: In allergic conjunctivitis, both olopatadine and azelastine were found to be effective in relieving ocular signs and symptoms, but olopatadine was found to be superior in terms of efficacy, safety and tolerability with minimal side effects.

Keywords: Allergic conjunctivitis, Azelastine hydrochloride 0.05% eye drops, Olopatadine hydrochloride 0.1% eye drops

INTRODUCTION

Allergic Conjunctival Diseases (ACD) are ocular disorders caused by allergic inflammation of the ocular surface and include Allergic conjunctivitis (AC), atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC) and giant papillary conjunctivitis. Allergic conjunctivitis is an ACD in which the conjunctiva shows no proliferative change and includes seasonal and perennial allergic conjunctivitis. About 15-20% of the population worldwide is affected by seasonal allergic conjunctivitis (SAC) which is a type 1 allergic reaction.1 SAC has a significant impact on the social and economic aspects of life by increasing health costs and number of disability days leading to absence from work and school.2,3

The principal symptom of Allergic Conjunctivitis is ocular itching. Other signs and symptoms include conjunctival redness, tearing, mucus discharge, chemosis and lid edema. Mast cells play an important role in the pathogenesis of Allergic Conjunctivitis. The binding of
specific antigens on mast cells in the conjunctiva leads to
mast cell degranulation and the release of mediators
including histamine, tryptase, leukotrienes, cytokines and
platelet activating factor. Histamine, being the principal
vasoactive amine, is said to be responsible for the major
signs and symptoms of allergic conjunctivitis.4,5

The most effective means of managing allergic
conjunctivitis is to identify the offending antigen and
avoid exposure to it. However, on most occasions either
the antigens are unidentifiable or exposure cannot be
avoided as they are airborne, making this approach
implausible.6 Thus pharmacological agents like NSAIDs,
H1 receptor blockers, mast cell stabilizers and drugs that
block cytokine and prostaglandin formation form the
treatment armamentarium. Topical antihistaminics,
because of their ability to provide rapid relief of signs and
symptoms, are the first line agents in the treatment of
ocular allergic disorders, but should not be used for more
than six weeks. On the contrary, Mast cell stabilizers
carry prophylactic value i.e., they prevent future
exacerbations but take 3-7 days to show an effect. They
can also be used for longer periods when necessary.7
Recently, dual action anti-allergic drugs having both
antihistaminic and mast cell-stabilizing properties have
been introduced which attack multiple facets of the
allergic cascade. Olopatadine hydrochloride 0.1% is one
such single molecule with dual properties inhibiting
immediate hypersensitivity reactions and providing long
term membrane stabilization.8 Azelastine, with similar
properties, provides immediate relief and the early-phase
intervention inhibits expression and activation of
inflammatory mediators which characterize the late phase
of the immune reaction.9 Both have been reported to be
effective and well tolerated in the treatment of allergic
conjunctivitis but the limited body of evidence amongst
Indian population prompted us to evaluate the efficacy
and safety of these two ocular preparations. The objective
of this study was to compare the reduction in the ocular
signs and symptoms scores, safety and tolerability of
olopatadine hydrochloride 0.1% eye drops versus
Azelastine 0.05% eye drops in the treatment of allergic
conjunctivitis in the Indian population.

METHODS

This was a prospective, randomized, open labelled study
conducted at outpatient department of Minto
Ophthalmology Hospital attached to Bangalore Medical
College and Research Institute between April 2014 and
June 2015. Patients of either sex aged 18-65 years
diagnosed with allergic conjunctivitis with grade 4
(severe) ocular itching and grade 2 or higher (i.e.,
moderate to severe) bulbar conjunctival injection were
included in the study. Patients not willing to give written
informed consent, pregnant and lactating women, patients
with known hypersensitivity to the study medications or
their components (including benzalkonium chloride) and
those on other medications which may interfere with the
study like decongestants, topical prostaglandin
derivatives, ocular or systemic NSAIDs and
corticosteroids were excluded from the study. Also not
included in the study were patients with an intraocular
pressure of more than 21 mm Hg in either eye, those
having active ocular infection, serious ocular pathological
conditions or have undergone ocular surgical
interventions within past 3 months and patients unwilling
to discontinue wearing contact lenses during the study.

After obtaining informed consent, 120 eligible patients
were randomized using a computer generated random
number table in a 1:1 ratio. Sixty patients were allocated
to each group to receive either olopatadine hydrochloride
0.1% eye drops 12th hourly or Azelastine hydrochloride
0.05% eye drops 12th hourly for 15 days. Demographic
data, ocular and medical history, concomitant
medications, physical examination, clinical examination
including recording of vital signs, ophthalmological
examination (ocular sign and symptom score) and details
of drug prescription were recorded in the study proforma
at baseline visit (visit 1) and all subsequent follow-up
visits.10,11

Follow-up visits were done on day 8 (visit 2) and day 15
(visit 3) after administering the study drugs. A deviation
of ±1 day for first follow-up and ±2 days for subsequent
follow-up was accepted. At each follow-up visit data on
concomitant medications, ocular symptoms such as
itching, foreign body sensation, stinging, photophobia,
watering was graded by the patients on a severity scale of
0 to 4.

Similarly, ocular signs such as congestion, erythema,
chemosis was graded by ophthalmologist on a severity
scale of 0 to 4. Safety was assessed by recording the
adverse effects at each follow up visit. Study medications
were dispensed once at baseline visit. During the study
period, subjects were not allowed to take any other
topical anti inflammatory drugs except for lubricating eye
drops.

A reduction in the ocular signs and symptoms score was
the primary efficacy parameter. Clinical Global
Impression of Change (CGIC) and Patient Global
Impression of Change (PGIC) were the secondary
efficacy parameters observed. Safety monitoring was
done continuously throughout the study. All adverse
effects spontaneously reported by the subjects or elicited
by the investigators were recorded.

Tolerability of the study medications was assessed by
administering the Global Evaluation of Overall
Tolerability (GEOT) scale to the patients which was
graded as excellent, good and poor. Compliance was
assessed with the help of a medication compliance card.
Non responders were defined as those who failed to
respond to the trial medication i.e. no reduction in the
baseline ocular signs and symptom score at day 8 (visit 1)
and thereby requiring additional medications such as
topical steroids and immunsuppressants.
RESULTS

Demographic characteristics

Both the study groups were age and gender matched. The mean age of the study participants was 23.3 years.

Efficacy parameters

Table 2 and Table 3 show the scores for allergic conjunctivitis signs and symptoms at each visit.

There were no significant differences among the groups regarding baseline scores. At each visit, in both groups, scores for ocular itching, eyelid erythema, chemosis, conjunctival congestion, watering, photophobia were reduced when compared to baseline and the improvement was significant in olopatadine group as compared to azelastine group.

Non responder rate was 6.6% in olopatadine group as compared to 15% in azelastine group and it was not statistically significant ($\chi^2= 2.15, df= 1, p= 0.1419$), as depicted in Figure 1.

Table 1: Demographic characteristics of the study subjects.

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Olopatadine group (n=60)</th>
<th>Azelastine group (n=60)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years (Mean±SD)</td>
<td>23.75±2.98</td>
<td>22.9±2.74</td>
<td>0.136</td>
</tr>
<tr>
<td>18-25 years</td>
<td>47</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>26-39 years</td>
<td>9</td>
<td>10</td>
<td>0.592</td>
</tr>
<tr>
<td>≥40 years</td>
<td>4</td>
<td>7</td>
<td>1.05, d.f=2</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>34</td>
<td>0.577</td>
</tr>
<tr>
<td></td>
<td>37</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>26</td>
<td>0.310, d.f=1</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occupation</td>
<td>Students</td>
<td>20</td>
<td>0.914</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Factory workers</td>
<td>18</td>
<td>0.972, d.f=4</td>
</tr>
<tr>
<td></td>
<td>19</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Outdoor workers</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unemployed</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Habits</td>
<td>Smokers</td>
<td>36</td>
<td>0.461</td>
</tr>
<tr>
<td></td>
<td>32</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-smokers</td>
<td>24</td>
<td>0.543, d.f=1</td>
</tr>
<tr>
<td></td>
<td>28</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Ocular symptoms scores of study subjects.

<table>
<thead>
<tr>
<th>Ocular symptoms</th>
<th>Olopatadine (n=60)</th>
<th>Azelastine (n=60)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Visit 1</td>
<td>Visit 2</td>
</tr>
<tr>
<td>Itching</td>
<td>3 (2-4)</td>
<td>2 (0-4)*</td>
<td>0 (0-4)*</td>
</tr>
<tr>
<td>FB sensation</td>
<td>3 (2-4)</td>
<td>2 (1-4)*</td>
<td>0 (0-4)*</td>
</tr>
<tr>
<td>Stinging</td>
<td>3 (2-4)</td>
<td>2 (0-4)</td>
<td>0 (0-4)*</td>
</tr>
<tr>
<td>Photophobia</td>
<td>3 (2-4)</td>
<td>1 (0-4)*</td>
<td>0 (0-4)*</td>
</tr>
<tr>
<td>Watering</td>
<td>3 (2-4)</td>
<td>2 (0-4)</td>
<td>0 (0-4)*</td>
</tr>
</tbody>
</table>

scores are depicted in median with range in bracket
*a* p<0.0001, ocular signs scores by F-ANOVA test at visit 1 and visit 2 compared to baseline in both the groups
£ p > 0.05, baseline characteristics between groups.

Table 3: Ocular sign scores of study subjects.

<table>
<thead>
<tr>
<th>Ocular signs</th>
<th>Olopatadine (n=60)</th>
<th>Azelastine (n=60)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Visit 1</td>
<td>Visit 2</td>
</tr>
<tr>
<td>Congestion</td>
<td>2(1-3)</td>
<td>1(0-3)*</td>
<td>0 (0-3)*</td>
</tr>
<tr>
<td>Erythema</td>
<td>2(1-3)</td>
<td>1(0-3)*</td>
<td>0 (0-3)*</td>
</tr>
<tr>
<td>Chemosis</td>
<td>2(1-3)</td>
<td>1(0-3)*</td>
<td>0 (0-3)*</td>
</tr>
</tbody>
</table>

scores are depicted in median with range in bracket
*a* p<0.0001, ocular signs scores by F-ANOVA test at visit 1 and visit 2 compared to baseline in both the groups
£ p > 0.05, baseline characteristics between groups.
Both the study medications were well tolerated. The Global Evaluation of Tolerability in both the study groups is depicted in Figure 4. All the study participants were 100% compliant.

**DISCUSSION**

Allergic conjunctivitis is a bilateral and self-limiting inflammatory process caused by an IgE-mediated immediate hypersensitivity reaction triggering mast cell activation and the release of various inflammatory mediators. These contribute to the appearance of the typical signs and symptoms that characterize the disease such as itching, redness, and tearing. Allergic conjunctivitis affects about 15-20% of the population worldwide and has a significant impact on the social and economic aspects of life. In the present study the efficacy, safety and tolerability of two topical dual acting anti-allergic drugs, olopatadine and azelastine were compared in patients with allergic conjunctivitis. All the patients recruited in the study were included for analysis as there were no drop outs. Non responders were treated with additional medications such as topical steroids and immunosuppressants. Intention to Treat analysis with Last Observation Carried Forward was done for non responders.

The peak incidence of Allergic conjunctivitis is documented in children and young adults, with no gender predilection. Majority of the patients (74.1%) in this study belonged to the 18-25 years age group and only 25.8% of the patients were above the age of 25 years. This was consistent with the studies done by John et al, and Abokyi et al, where the mean age of allergic conjunctivitis patients was about 20 years. A study done in Spain revealed both children and adults were most commonly affected with allergic conjunctivitis. However, patients less than 18 years were not included in the present study. In the current study, the two groups were gender matched. Among the subjects enrolled in the two groups there were a total of 71 males and 49 females,

**Table 4: Ocular adverse effects.**

<table>
<thead>
<tr>
<th>Adverse effects</th>
<th>Olopatadine group</th>
<th>Azelastine group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of patients: 60 (%)</td>
<td></td>
</tr>
<tr>
<td>Stinging</td>
<td>8 (13)</td>
<td>28 (47)</td>
</tr>
<tr>
<td>Burning</td>
<td>9 (15)</td>
<td>26 (43)</td>
</tr>
<tr>
<td>Headache</td>
<td>03 (5)</td>
<td>02 (3)</td>
</tr>
<tr>
<td>Bitter taste</td>
<td>11 (18)</td>
<td>18 (30)</td>
</tr>
<tr>
<td>No adverse effect</td>
<td>32 (53)</td>
<td>10 (17)</td>
</tr>
</tbody>
</table>
but this difference too was not statistically significant. A similar trend was also observed in a study done in Greece. However, a cross sectional study done in UAE (76% females vs 24% males) revealed female preponderance as compared to males which was statistically significant.16

Work-related allergic conjunctivitis has been increasingly reported amongst workers exposed to common environmental allergens. Factory and outdoor workers are at an increased risk of such allergic reactions.15 31% and 21% of the study participants were factory and outdoor workers respectively. This fact is well asserted in a comparative study done in sawmill workers which showed that the incidence of allergic conjunctivitis was more in the technical workers than the administrative workers.19

Several eye disorders are seen in smokers and those who are frequently exposed to tobacco smoke. Allergic conjunctivitis is the most common disease affected by environmental variations. Smoking affects the ocular surface, which results in symptoms like itchiness, redness and irritation of eyes. The changes on ocular surface associated with smoking include alteration in lipid layer of tear film, reduced tear secretion and decreased corneal and conjunctival sensitivity.20 While no studies have been conducted specifically to assess the relationship between allergic conjunctivitis and tobacco smoke exposure, a number of studies of allergic reactions in children have reported that the risk of developing allergic conjunctivitis is increased by about 20% in children who are exposed to environmental tobacco smoke. Even in adults smoking has been linked to an increase in ocular surface disorders.21 In the present study, 57% of the allergic conjunctivitis patients were smokers. But to draw a conclusion with this data would not be apt as passive smoking can also increase the risk of these disorders.

In this comparative study, two topical dual acting ocular antihistamines, olopatadine and azelastine, were evaluated for their efficacy and safety in allergic conjunctivitis. Efficacy was evaluated primarily as a reduction in the ocular signs and symptoms scores. The basal ocular signs and symptoms scores were comparable between the two groups. Olopatadine and azelastine, both effectively reduced the scores at the subsequent follow up visits (day 8 and day 15), but the reduction in the olopatadine treated group was significantly larger compared to patients treated with azelastine. At the end of the study period, the reduction in the ocular itching score from baseline was higher in the olopatadine group (3 vs 0) as compared to the azelastine group (3 vs 1). The reduction in ocular congestion score was also higher in the olopatadine group (3 vs 0) as compared to the azelastine group (3 vs 1). Similarly, the scores of foreign body sensation (p<0.009), stinging (p<0.001), photophobia (p<0.016), tearing (p<0.001), erythema (p<0.002) and chemosis (p<0.015) also showed larger reduction in the olopatadine treated patients compared to the azelastine group. The olopatadine treated patients also showed a lower rate of nonresponders (6.6%) when compared to patients treated with azelastine (15%), though the difference was not statistically significant ($\chi^2$=3.27, df=1, p=0.071). Hence olopatadine was found to be a more potent and effective dual acting antihistaminic in the treatment of allergic conjunctivitis compared to azelastine.

The findings of this study are consistent with the outcomes noted in the two prospective studies comparing olopatadine and azelastine, the patient-reported PACE study and the investigator-reported CAC study.13,22 The recent major multicenter, prospective, open-label PACE (Pataday Allergic Conjunctivitis Evaluation) study conducted by Ophthalmic Research Associates, which included 49 patients of allergic conjunctivitis showed that 42% of olopatadine treated patients reported an improvement in itching as compared to only 17% of them treated with azelastine. A reduction in congestion was also reported by a greater number of patients in the olopatadine group (46%) compared to the azelastine group (20%). Spangler and colleagues, in the conjunctival allergen challenge (CAC) model, demonstrated that both olopatadine and azelastine were significantly more effective than placebo at reducing itching postchallenge. However, olopatadine was significantly more effective than azelastine in reducing itching at 3.5 minutes postchallenge (p <0.05). On the contrary, in a survey done at 75 ophthalmologist/ optometrist clinics in South Florida, azelastine was favoured to be more effective and yield higher patient satisfaction score than olopatadine in the treatment of allergic conjunctivitis.23

Safety evaluation was another important objective of this study. While 83% of the patients in azelastine group experienced adverse effects, only 47% of the patients in olopatadine group reported the same. All the adverse effects encountered were mild to moderate local ocular adverse effects and did not require any medical intervention. There were no serious adverse effects observed in either group. Common adverse effects seen in both the groups were stinging after instillation, burning, bitter taste and headache. Burning (26 vs 9) and stinging (28 vs 8) was seen in more number of patients receiving azelastine as compared to those receiving olopatadine which was statistically significant ($\chi^2$=24.9, df=1, p = 0.000). Both the study medications were well tolerated as assessed with the Global Evaluation of Tolerability scale. All the study participants were 100% compliant. An identical adverse effect and tolerability profile has been observed in various studies conducted with olopatadine and azelastine. The PACE study also reported similar adverse effects with the study medications, however with a lower incidence rate. The superior comfort with olopatadine compared to azelastine though not been clearly defined, may be at least partly attributed to pH differences.24 Azelastine has a more acidic pH ranging from 5.0 to 6.5, whereas olopatadine
has a physiological pH of approximately 7. Another possible explanation could be due to the differing effects of these drugs on cell membrane integrity. Olopatadine, unlike azelastine and other dual-action agents, does not perturb the membranes of ocular surface epithelial cells, the damage of which may lead to stinging and burning that is encountered upon instillation of these other agents.  

While the strengths of this study include its prospective and randomized study design, an open labelled design remains its limitation. The efficacy and safety of the study medications was also not assessed in the pediatric patients, among whom a higher incidence of allergic conjunctivitis is commonly seen. Further more, elaborate studies evaluating the factors contributing to allergic conjunctivitis, its prognosis and their intervening effects on drug actions may be worth undertaking.

**CONCLUSION**

In allergic conjunctivitis, both olopatadine and azelastine were found to be effective in relieving ocular signs and symptoms, but olopatadine was found to be superior in terms of efficacy with minimal side effects.

**Funding: No funding sources**  
**Conflict of interest: None declared**  
**Ethical approval: The study was approved by the Institutional Ethics Committee**

**REFERENCES**
